摘要
目前非小细胞肺癌的免疫治疗正迅速发展,其中CIMAvax-EGF疫苗是一种古巴独立研制开发的治疗性肺癌疫苗,其机制是通过疫苗接种而形成抗表皮生长因子(EGF)抗体,从而阻断EGF与其受体的结合而发挥抗癌作用。目前Ⅱ期和Ⅲ期试验已经证明了该疫苗的有效性和长期安全性,新的Ⅲ期和Ⅳ期试验正在进行中。了解CIMAvax-EGF在非小细胞肺癌中的应用,将有助于加速肺癌的免疫治疗进程,本文总结了CIMAvax-EGF在非小细胞肺癌中的治疗进展。
The past few years have witnessed rapid advances in the immunotherapies for non-small-cell lung cancer（ NSCLC）. CIMAvax-EGF is a therapeutic vaccine against lung cancer independently developed by Cuba. It can exert its anti-tumor effect by forming epidermal growth factor（ EGF） antibodies to block the binding of EGF to EGF receptor. So far stage both phases Ⅱ and Ⅲ trials have proved its effectiveness and long-term safety,and phases Ⅲ and Ⅳ trials are underway. A deeper understanding of the role of CIMAvax-EGF in NSCLC will accelerate the application of immunotherapy. This article summarizes the recent advances of CIMAvax-EGF RD and its application in treating NSCLC.
作者
张佳颖
朱磊
杨宏宽
陈芳
ZHANG Jiaying;ZHU Lei;YANG Hongkuan;CHEN Fang(First Clinical Medical College,Zhejiang Chinese Medicine University,Hangzhou 310053,China;Department of Lung Function,First Affiliated Hospital,Zhejiang Chinese Medicine University,Hangzhou 310006)
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2018年第3期411-414,共4页
Acta Academiae Medicinae Sinicae
基金
浙江省中医药科学研究基金(2018ZA039)~~
